P2X7-CAR T cells

P2X7-CAR T cells (including those targeting the non-functional variant nfP2X7) are chimeric antigen receptor (CAR) T-cell therapies designed to target the P2X7 purinergic receptor, an ATP-gated ion channel that is aberrantly expressed or in a non-functional conformation (nfP2X7) on various cancer cells while remaining largely absent or inaccessible on healthy tissues. Developed by companies like Biosceptre and Carina Biotech, these cell therapies aim to provide a broad-spectrum, highly selective treatment for solid tumors (such as ovarian, breast, prostate, and lung cancers) and hematological malignancies by inducing antigen-specific cytotoxicity and tumor cell lysis without damaging normal tissues.

Other names

anti-nfP2X7 CAR-T cellsanti-nfP-2X7 CAR-T cellsanti-nfP 2X7 CAR-T cellsanti-P2X7 CAR-T cellsanti-P-2X7 CAR-T cellsanti-P 2X7 CAR-T cellsnfP2X7 CAR-TnfP-2X7 CAR-TnfP 2X7 CAR-TnfP2X7 CAR-T cellsnfP-2X7 CAR-T cellsnfP 2X7 CAR-T cellsnfP2X7-CAR T cellsnfP-2X7-CAR T cellsnfP 2X7-CAR T cellsnon-functional P2X7 CAR-T cellsP2X7 CAR-TP-2X7 CAR-TP 2X7 CAR-TP2X7 CAR-T cellsP-2X7 CAR-T cellsP 2X7 CAR-T cells